The top after-market NASDAQ Stock Market gainers are: Select Comfort, Plexus, F5 Networks, Datalink, TradeStation Group, Qualcomm, and Apple. The top after-market NASDAQ Stock Market losers are: Lam Research, Sina, Gilead Sciences, Amgen, and Cheesecake Factory.

Gainers

Select Comfort Corp. (SCSS) stock jumped 20.57 percent to $16 in the after-market trading, as its first quarter earnings and sales exceeded Street view. Profit was $16.6 million or 30 cents a share, up from $7.8 million or 14 cents a share last year. Sales grew 22 percent to $193.1 million, driven by a company-owned comparable sales growth of 26 percent. Analysts had expected profit of 19 cents a share on revenue of $166.56 million.

The company raised its fiscal 2011 earnings guidance to range of 85 cents to 93 cents a share from previous forecast of 68 cents to 74 cents a share, while Street analysts predict 71 cents a share.

Plexus Corp. (PLXS) stock climbed 15.68 percent to $39.02 in the after-market trading, as it guided third quarter above Street view. The company expects third quarter earnings of 52 cents to 57 cents a share, excluding any restructuring charges and including about 7 cents a share of stock-based compensation expense, and revenues of $550 million to $580 million. Street predicts profit of 48 cents a share on revenue of $538.45 million.

Plexus reported second quarter earnings of $23.9 million or 59 cents a share, up from $20.7 million or 51 cents a share last year. Revenue rose to $568.2 million from $491.0 million. Analysts had expected profit of 56 cents a share on revenue of $558.55 million.

F5 Networks, Inc. (FFIV) stock advanced 12.53 percent to $112.24 in the after-market trading, as its second quarter earnings exceeded Street view. Adjusted profit was $71.5 million or 88 cents a share, up from $45.2 million or 56 cents a share last year. Revenue grew 34.7 percent to $277.6 million. Analysts had expected profit of 86 cents a share on revenue of $277.68 million. The company expects third quarter adjusted earnings of 89 cents to 91 cents a share and revenue of $287 million to $292 million, while Street predicts profit of 89 cents a share on revenue of $290.32 million.

Datalink Corp. (DTLK) stock improved 11.08 percent to $6.92 in the after-market trading, as its first quarter earnings and revenue exceeded Street view. Adjusted profit was $2.2 million or 16 cents a share, up from $107,000 or 1 cent a share last year. Revenue grew 37 percent to $85.7 million. Analysts had expected profit of 12 cents a share on revenue of $79.67 million. The company expects second quarter adjusted earnings of 9 cents to 13 cents a share and revenue of $80 million to $86 million, while Street predicts profit of 9 cents a share on revenue of $76.70 million.

TradeStation Group Inc. (TRAD) stock grew 7.96 percent to $8 in the after-market trading, as it agreed to be acquired by Monex Group Inc. for about $411 million. TradeStation's shareholders will receive $9.75 in cash for each share, which represents a 32 percent premium to TradeStation's closing stock price on April 20. Monex will commence a tender offer for all of the outstanding shares of TradeStation by May 10. If the tender offer is successfully completed, the parties expect the transaction to close early in the 2011 third quarter.

Qualcomm Inc. (QCOM) stock gained 5.19 percent to $58.14 in the after-market trading, as its second quarter earnings exceeded Street view. Profit was $999 million or 59 cents a share, up from $774 million or 46 cents a share last year. Adjusted earnings were $1.45 billion or 86 cents a share for the latest quarter. Revenue grew 46 percent to $3.87 billion. Analysts had expected profit of 80 cents a share on revenue of $3.62 billion.

Qualcomm expects third quarter adjusted earnings of 68 cents to 72 cents a share and revenue of $3.35 billion to $3.65 billion, while Street predicts profit of 69 cents a share on revenue of $3.39 billion. The company raised its fiscal 2011 adjusted profit guidance to range of $3.05 to $3.13 a share from previous forecast of $2.91 to $3.05 a share. The company also increased its 2011 revenue outlook to range of $14.1 billion to $14.7 billion from previous range of $13.6 billion to $14.2 billion. Analysts expect profit of $3.04 a share on revenue of $13.93 billion for fiscal 2011.

Apple Inc. (AAPL) stock increased 3.10 percent to $353.02 in the after-market trading, as its second quarter earnings and revenue exceeded Street view. Profit was $6.0 billion or $6.40 a share, up from $3.1 billion or $3.33 a share last year. Sales rose to $24.7 billion from $13.5 billion. Analysts had expected profit of $5.36 a share on revenue of $23.34 billion.

During the second quarter, Apple said it sold 3.76 million Macs, a 28 percent unit increase over the year-ago quarter. The company sold 18.65 million iPhones, representing 113 percent unit growth over last year. Apple sold 9.02 million iPods, representing a 17 percent unit decline from year-ago. The company also sold 4.69 million iPads during the second quarter. The company expects third quarter earnings of about $5.03 a share and revenue of about $23 billion, while Street predicts profit of $5.25 a share on revenue of $23.82 billion.

Losers

Lam Research Corp. (LRCX) stock fell 5.02 percent to $49.43 in the after-market trading. Profit for the third quarter was $182.2 million or $1.45 a share, up from $120.3 million or $0.94 a share last year. Revenue rose to $809 million from $632.7 million. Analysts had expected profit of $1.36 a share on revenue of $804.93 million. Looking ahead, the company sounded confident for the future as demand for smartphones and other electronic devices would likely drive a healthy level of investment on the part of its customers over the course of calendar 2011.

In the conference call, Lam Research said it expects fourth quarter earnings of $1.07 a share, plus or minus $0.07 a share, and revenue of $745 million, plus or minus $20 million. Street analysts predict profit of $1.39 a share on revenue of $830.59 million for the fourth quarter. The company forecasts fourth quarter shipments of $780 million, plus or minus $25 million.

Sina Corp. (SINA) stock tumbled 3.24 percent to $138.20 in the after-market trading.

Gilead Sciences Inc. (GILD) stock slid 2.53 percent to $39.75 in the after-market trading, as its first quarter earnings fell 24 percent due to drop in Tamilflu royalties and lower margins. Adjusted profit was $702.8 million or 87 cents a share, down from $914.8 million or 99 cents a share last year. Revenue fell 8 percent to $1.93 billion. Analysts had expected profit of 97 cents a share on revenue of $2.04 billion.

Royalty, contract and other revenues for the quarter plunged 79 percent to $62.52 million, due to a 95 percent drop in Tamiflu royalties from F. Hoffmann-La Roche Ltd. resulting from a decline in pandemic planning initiatives worldwide. Product gross margin for the quarter slid to 74.6 percent from 75.5 percent, while operating margin declined to 46.8 percent from 55.7 percent. Looking forward, the company reiterated its fiscal 2011 product sales outlook of $7.9 billion to $8.1 billion.

Amgen Inc. (AMGN) stock declined 2.10 percent to $55 in the after-market trading. Adjusted profit for the first quarter was $1.26 billion or $1.34 a share, compared to $1.28 billion or $1.30 a share last year. Revenue rose 3 percent to $3.71 billion. Analysts had expected profit of $1.29 a share on revenue of $3.68 billion. The company reaffirmed its 2011 adjusted earnings guidance of $5.00 to $5.20 a share and revenue outlook of $15.1 billion to $15.5 billion, while Street predicts profit of $5.14 a share on revenue of $15.23 billion.

Separately on Thursday, Amgen along with UCB announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density for the treatment of postmenopausal osteoporosis. Amgen said the Phase 2 study met its primary endpoint, demonstrating significant increases in lumbar spine bone mineral density at month 12 for the AMG 785/CDP7851 active arms versus the placebo arm.

Besides, AMG 785/CDP7851 compared positively with the two active comparators, teriparatide and alendronate. Amgen stated the overall incidence of adverse events was generally balanced between groups. Consistent with former studies, injection site reactions were reported more frequently in those patients receiving AMG 785/CDP7851.

The Cheesecake Factory Inc. (CAKE) stock decreased 1.96 percent to $30 in the after-market trading. Profit for the first quarter was $20.5 million or 34 cents a share, up from $18.7 million or 31 cents a share last year. Revenue rose to $418.8 million from $405.4 million. Analysts had expected profit of 33 cents a share on revenue of $418.75 million. Comparable restaurant sales increased 1.6 percent from last year.

Looking forward, the company expects to deliver annual, mid-teens earnings growth over the next five years. We are confident in our ability to achieve this objective, as we are continuing to attract higher levels of guest traffic and effectively managing our operations to leverage incremental sales, Overton added.

In the conference call, Cheesecake said it expects second quarter earnings of 39 cents to 41 cents a share, based on an assumed range of comparable sales between 1.5 percent and 3 percent. For the full year 2011, the company expects earnings of $1.58 to $1.70, based on an assumed comparable sales range of between 1.5 percent and 3 percent. Street analysts predict profit of 45 cents a share for the second quarter, and $1.64 a share for the full year 2011.